Tandem Diabetes Care, Inc. announced the commercial launch of its Control-IQ+ technology in the United States. This latest generation of the company’s advanced hybrid closed-loop algorithm is now available for individuals with type 1 diabetes aged 2 years and older, and for adults with type 2 diabetes. The technology is compatible with both the t:slim X2 insulin pump and the Tandem Mobi System.
New customers will receive pumps pre-loaded with the updated software, while all eligible, in-warranty Tandem customers can access the new features via a remote software update at no charge. Control-IQ+ builds on the existing Control-IQ algorithm, which adjusts insulin every 5 minutes based on predicted glucose values and includes an AutoBolus feature for correction boluses. It is also the only AID algorithm that allows users to program extended boluses of up to 8 hours while automation is active.
This launch expands the availability of Tandem's life-changing technology to millions more people living with diabetes. The enhanced features allow for greater personalization and flexibility, while maintaining ease of use across a diverse population of users.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.